COVID-19 specific antibody testing in ALSPAC (G0/G1) [COVID-19]
Research type
Research Study
Full title
COVID-19 specific antibody testing in ALSPAC (G0/G1)
IRAS ID
296091
Contact name
Nicholas Timpson
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
1 years, 0 months, 7 days
Research summary
The study aims to estimate how many people in ALSPAC have been infected with the virus that causes COVID-19. We don’t know yet if having antibodies gives someone long-lasting protection from the virus. The results of this study may help guide public health policy and the government’s plan for its antibody testing strategy.
Other population-based research studies in the UK are also asking their participants to complete the same antibody test. Analysing the information from ALSPAC alongside these other studies will allow a greater understanding of variations across ethnicity, age, socio-economic status and geography.
We can use these antibody test results in several ways alongside information already collected in ALSPAC. Such as information on COVID-19 symptoms, (already collected via questionnaires) medical outcomes, (through record linkage), and data from other clinics and questionnaires that could be related.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
21/EE/0061
Date of REC Opinion
3 Mar 2021
REC opinion
Further Information Favourable Opinion